Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT

Jacobson, Ira M.; Ahmed, Furqaan; Russo, Mark W; Lebovics, Edward; Dieterich, Douglas T.; Esposito, Stephen P.; Bach, Nancy; Klion, Franklin; Tobias, Hillel; Antignano, Louis; Brown Jr., Robert S.; Gabbaizadeh, David; Geders, Jane; Levendoglu, Hulya
September 2004
American Journal of Gastroenterology;Sep2004, Vol. 99 Issue 9, p1700
Academic Journal
OBJECTIVES: Most studies establishing the role of antiviral therapy in patients with chronic hepatitis C (CHC) excluded the patients with normal ALT levels. Small trials with interferon monotherapy suggested a limited efficacy and/orde novoALT elevations. We sought to evaluate the efficacy of two doses of interferon alpha-2b (IFN) with ribavirin (RBV) in patients with normal ALT.METHODS: Patients with biopsy-proven CHC with detectable HCV RNA and at least two normal ALT levels three or more months apart were randomized to receive either 3 or 5 million units of IFN thrice a week plus RBV 1,000–1,200 mg. Therapy was stopped at 24 wk if HCV RNA remained detectable and continued for an additional 24 wk if HCV RNA was undetectable. A final HCV RNA level was obtained 24 wk after discontinuation of therapy.RESULTS: Fifty-six patients were randomized and received at least one dose of treatment. The overall rate of sustained virologic response (SVR) was 32%. SVR rates were higher in genotype 2 and 3 patients (80%) than in genotype 1 patients (24%,p= 0.002). There was a tendency toward higher SVR in genotype 1 patients treated with the higher IFN dose (36%vs10%, p= 0.07). Five patients had mild, transient ALT elevations. No sustained ALT elevations were noted.CONCLUSIONS: Patients with normal ALT had a rate of SVR comparable to that reported in patients with elevated ALT. Higher dose of interferon tended to be more effective in genotype 1 infected patients.De novoALT elevations were transient and not clinically significant. Patients with CHC should not be excluded from treatment on the basis of ALT alone. Combination therapy with pegylated interferon and ribavirin should be evaluated in these patients.(Am J Gastroenterol 2004;99:1700-1705)


Related Articles

  • Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b. Jensen, Donald M.; Marcellin, Patrick; Freilich, Bradley; Andreone, Pietro; Di Bisceglie, Adrian; Brandão-Mello, Carlos E.; Reddy, K. Rajender; Craxi, Antonio; Martin, Antonio Olveira; Teuber, Gerlinde; Messinger, Diethelm; Thommes, James A.; Tietz, Andreas // Annals of Internal Medicine;4/21/2009, Vol. 150 Issue 8, p528 

    Background: Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin. Objective: To evaluate use of peginterferon-α2a plus ribavirin to re-treat nonresponders to peginterferon-α2b plus ribavirin. Design: Randomized, parallel-group trial...

  • Enhanced anti-HCV activity of interferon alpha 17 subtype. Dubois, Aurelie; François, Catherine; Descamps, Veronique; Fournier, Carole; Wychowski, Czeslaw; Dubuisson, Jean; Castelain, Sandrine; Duverlie, Gilles // Virology Journal;2009, Vol. 6, p1 

    Background: Pegylated interferon alpha 2 (a or b) plus ribavirin is the most effective treatment of chronic hepatitis C but a large proportion of patients do not respond to therapy. So, it is interesting to improve the treatment efficacy. Interferon alpha is a type I interferon composed of 12...

  • Ribavirin concentration in the later stages of 48 week pegylated interferon-α2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. Furusyo, Norihiro; Murata, Masayuki; Ogawa, Eiichi; Toyoda, Kazuhiro; Ihara, Takeshi; Ikezaki, Hiroaki; Hayashi, Takeo; Koga, Tsunehisa; Kainuma, Mosaburo; Hayashi, Jun // Journal of Antimicrobial Chemotherapy (JAC);May2011, Vol. 66 Issue 5, p1127 

    Objectives The current standard of care for chronic hepatitis C patients is a pegylated interferon-α plus ribavirin combination treatment. This study was carried out to determine the relationship between ribavirin concentration in the later stages of treatment and virological relapse....

  • Hepatitis C Treatment: Trial by Design. Bzeizi, Khalid I. // Saudi Journal of Gastroenterology;Apr-Jun2008, Vol. 14 Issue 2, p51 

    The author comments on the findings of a study about the treatment outcome of 335 hepatitis C virus (HCV) patients treated with peginterferon α-2a and ribavirin combination therapy in Saudi Arabia. He states that the divergence of the study's findings from the prospective studies published...

  • Peginterferon-α-2a (40kD) plus ribavirin: a new treatment option takes flight in chronic hepatitis C.  // Drugs & Therapy Perspectives;Feb2004, Vol. 20 Issue 2, p1 

    Combination therapy with peginterferon-α-2a (40kD) [Pegasys®] plus ribavirin (Copegus™, Rebetol®) is a valuable new option for the first-line treatment of chronic hepatitis C. With regard to the sustained virological response rate, peginterferon-α-2a (40kD) plus ribavirin...

  • Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. Lok, Anna S.; Gardiner, David F.; Lawitz, Eric; Martorell, Claudia; Everson, Gregory T.; Ghalib, Reem; Reindollar, Robert; Rustgi, Vinod; McPhee, Fiona; Wind-Rotolo, Megan; Persson, Anna; Zhu, Kurt; Dimitrova, Dessislava I.; Eley, Timothy; Guo, Tong; Grasela, Dennis M.; Pasquinelli, Claudio // New England Journal of Medicine;1/19/2012, Vol. 366 Issue 3, p216 

    Background: Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen. Methods: This open-label, phase 2a study included an...

  • Therapy of Acute Hepatitis C: A Review of Literature. Santantonio, T.; Fasano, M. // Current Pharmaceutical Design;Jun2008, Vol. 14 Issue 17, p1686 

    The goal of treatment for acute hepatitis C patients is to eradicate the virus in the early phase of infection, thus preventing progression to chronicity. Early interferon (IFN) monotherapy has been shown to significantly reduce this risk, and therefore it has been recommended by international...

  • Cost Effectiveness of Peginterferon α-2a Plus Ribavirin versus Interferon α-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C. Arguedas, Miguel // PharmacoEconomics;2004, Vol. 22 Issue 7, p477 

    The article presents information on the cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment of chronic hepatitis C. Hepatitis C virus infection has become a worldwide problem, not only in terms of morbidity and...

  • Duration and Dose of Antiviral Treatment for Chronic Hepatitis C.  // Annals of Internal Medicine;3/2/2004, Vol. 140 Issue 5, pI67 

    Reports on the duration and dose of antiviral treatment for Chronic Hepatitis C. Effective combination of a long-acting immunity-boosting protein with another antiviral drug in ridding the body of HCV; Requirement of higher ribavirin doses by the patients with chronic hepatitis and HCV genotype 1.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics